NRF2 regulates HER1 signaling pathway to modulate the sensitivity of ovarian cancer cells to lapatinib and erlotinib

Ibrahim Hamza Kankia, Hilal S. Khalil, Simon P. Langdon, Peter R. Moult, James L. Bown, Yusuf Y. Deeni

    Research output: Contribution to journalArticle

    1 Citation (Scopus)
    15 Downloads (Pure)

    Abstract

    NF-E2-related factor 2 (NRF2) regulates the transcription of a battery of metabolic and cytoprotective genes. NRF2 and epidermal growth factor receptors (EGFRs/HERs) are regulators of cellular proliferation and determinants of cancer initiation and progression. NRF2 and HERs confer cancers with resistance to several therapeutic agents. Nevertheless, there is limited understanding of the regulation of HER expression and activation and the link between NRF2 and HER signalling pathways. We show that NRF2 regulates both basal and inducible expression of HER1, as treatment of ovarian cancer cells (PEO1, OVCAR3, and SKOV3) with NRF2 activator tBHQ inducing HER1, while inhibition of NRF2 by siRNA knockdown or with retinoid represses HER1. Furthermore, treatment of cells with tBHQ increased total and phosphorylated NRF2, HER1, and AKT levels and compromised the cytotoxic effect of lapatinib or erlotinib. Treatment with siRNA or retinoid antagonised the effect of tBHQ on NRF2 and HER1 levels and enhanced the sensitivity of ovarian cancer cells to lapatinib or erlotinib. Pharmacological or genetic inhibition of NRF2 and/or treatment with lapatinib or erlotinib elevated cellular ROS and depleted glutathione. This extends the understanding of NRF2 and its regulation of HER family receptors and opens a strategic target for improving cancer therapy.
    Original languageEnglish
    Article number1864578
    Number of pages19
    JournalOxidative Medicine and Cellular Longevity
    Volume2017
    DOIs
    Publication statusPublished - 19 Dec 2017

    Fingerprint

    NF-E2-Related Factor 2
    Ovarian Neoplasms
    Cells
    Retinoids
    Small Interfering RNA
    lapatinib
    Erlotinib Hydrochloride
    Neoplasms
    Transcription
    Glutathione

    Cite this

    Hamza Kankia, Ibrahim ; Khalil, Hilal S. ; Langdon, Simon P. ; Moult, Peter R. ; Bown, James L. ; Deeni, Yusuf Y. / NRF2 regulates HER1 signaling pathway to modulate the sensitivity of ovarian cancer cells to lapatinib and erlotinib. In: Oxidative Medicine and Cellular Longevity. 2017 ; Vol. 2017.
    @article{de59cd05f67d4e42afd7891bec07bd3f,
    title = "NRF2 regulates HER1 signaling pathway to modulate the sensitivity of ovarian cancer cells to lapatinib and erlotinib",
    abstract = "NF-E2-related factor 2 (NRF2) regulates the transcription of a battery of metabolic and cytoprotective genes. NRF2 and epidermal growth factor receptors (EGFRs/HERs) are regulators of cellular proliferation and determinants of cancer initiation and progression. NRF2 and HERs confer cancers with resistance to several therapeutic agents. Nevertheless, there is limited understanding of the regulation of HER expression and activation and the link between NRF2 and HER signalling pathways. We show that NRF2 regulates both basal and inducible expression of HER1, as treatment of ovarian cancer cells (PEO1, OVCAR3, and SKOV3) with NRF2 activator tBHQ inducing HER1, while inhibition of NRF2 by siRNA knockdown or with retinoid represses HER1. Furthermore, treatment of cells with tBHQ increased total and phosphorylated NRF2, HER1, and AKT levels and compromised the cytotoxic effect of lapatinib or erlotinib. Treatment with siRNA or retinoid antagonised the effect of tBHQ on NRF2 and HER1 levels and enhanced the sensitivity of ovarian cancer cells to lapatinib or erlotinib. Pharmacological or genetic inhibition of NRF2 and/or treatment with lapatinib or erlotinib elevated cellular ROS and depleted glutathione. This extends the understanding of NRF2 and its regulation of HER family receptors and opens a strategic target for improving cancer therapy.",
    author = "{Hamza Kankia}, Ibrahim and Khalil, {Hilal S.} and Langdon, {Simon P.} and Moult, {Peter R.} and Bown, {James L.} and Deeni, {Yusuf Y.}",
    year = "2017",
    month = "12",
    day = "19",
    doi = "10.1155/2017/1864578",
    language = "English",
    volume = "2017",
    journal = "Oxidative Medicine and Cellular Longevity",
    issn = "1942-0900",
    publisher = "Hindawi Publishing Corporation",

    }

    NRF2 regulates HER1 signaling pathway to modulate the sensitivity of ovarian cancer cells to lapatinib and erlotinib. / Hamza Kankia, Ibrahim; Khalil, Hilal S.; Langdon, Simon P.; Moult, Peter R.; Bown, James L.; Deeni, Yusuf Y.

    In: Oxidative Medicine and Cellular Longevity, Vol. 2017, 1864578, 19.12.2017.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - NRF2 regulates HER1 signaling pathway to modulate the sensitivity of ovarian cancer cells to lapatinib and erlotinib

    AU - Hamza Kankia, Ibrahim

    AU - Khalil, Hilal S.

    AU - Langdon, Simon P.

    AU - Moult, Peter R.

    AU - Bown, James L.

    AU - Deeni, Yusuf Y.

    PY - 2017/12/19

    Y1 - 2017/12/19

    N2 - NF-E2-related factor 2 (NRF2) regulates the transcription of a battery of metabolic and cytoprotective genes. NRF2 and epidermal growth factor receptors (EGFRs/HERs) are regulators of cellular proliferation and determinants of cancer initiation and progression. NRF2 and HERs confer cancers with resistance to several therapeutic agents. Nevertheless, there is limited understanding of the regulation of HER expression and activation and the link between NRF2 and HER signalling pathways. We show that NRF2 regulates both basal and inducible expression of HER1, as treatment of ovarian cancer cells (PEO1, OVCAR3, and SKOV3) with NRF2 activator tBHQ inducing HER1, while inhibition of NRF2 by siRNA knockdown or with retinoid represses HER1. Furthermore, treatment of cells with tBHQ increased total and phosphorylated NRF2, HER1, and AKT levels and compromised the cytotoxic effect of lapatinib or erlotinib. Treatment with siRNA or retinoid antagonised the effect of tBHQ on NRF2 and HER1 levels and enhanced the sensitivity of ovarian cancer cells to lapatinib or erlotinib. Pharmacological or genetic inhibition of NRF2 and/or treatment with lapatinib or erlotinib elevated cellular ROS and depleted glutathione. This extends the understanding of NRF2 and its regulation of HER family receptors and opens a strategic target for improving cancer therapy.

    AB - NF-E2-related factor 2 (NRF2) regulates the transcription of a battery of metabolic and cytoprotective genes. NRF2 and epidermal growth factor receptors (EGFRs/HERs) are regulators of cellular proliferation and determinants of cancer initiation and progression. NRF2 and HERs confer cancers with resistance to several therapeutic agents. Nevertheless, there is limited understanding of the regulation of HER expression and activation and the link between NRF2 and HER signalling pathways. We show that NRF2 regulates both basal and inducible expression of HER1, as treatment of ovarian cancer cells (PEO1, OVCAR3, and SKOV3) with NRF2 activator tBHQ inducing HER1, while inhibition of NRF2 by siRNA knockdown or with retinoid represses HER1. Furthermore, treatment of cells with tBHQ increased total and phosphorylated NRF2, HER1, and AKT levels and compromised the cytotoxic effect of lapatinib or erlotinib. Treatment with siRNA or retinoid antagonised the effect of tBHQ on NRF2 and HER1 levels and enhanced the sensitivity of ovarian cancer cells to lapatinib or erlotinib. Pharmacological or genetic inhibition of NRF2 and/or treatment with lapatinib or erlotinib elevated cellular ROS and depleted glutathione. This extends the understanding of NRF2 and its regulation of HER family receptors and opens a strategic target for improving cancer therapy.

    U2 - 10.1155/2017/1864578

    DO - 10.1155/2017/1864578

    M3 - Article

    VL - 2017

    JO - Oxidative Medicine and Cellular Longevity

    JF - Oxidative Medicine and Cellular Longevity

    SN - 1942-0900

    M1 - 1864578

    ER -